Renata Cifkova
First Faculty of Medicine, Charles University in Prague
327 Papers
2.3K Citations
Renata Cifkova is an academic researcher from First Faculty of Medicine, Charles University in Prague. The author has contributed to research in topics: Medicine & Population. The author has an hindex of 68, co-authored 305 publications. Previous affiliations of Renata Cifkova include Masaryk University & Czechoslovak Academy of Sciences.
Chat about Author
Papers
Aspirin for Secondary Prevention of Cardiovascular Disease in 51 Low-, Middle-, and High-Income Countries.
Sang Gune Kyle Yoo,Grace S. Chung,Silver Bahendeka,Abla M. Sibai,Albertino Damasceno,Farshad Farzadfar,Peter Rohloff,Corine Houehanou,Bolormaa Norov,Khem Bahadur Karki,Mohammadreza Azangou-Khyavy,Maja E Marcus,Krishna K. Aryal,L. C. Brant,Michaela Theilmann,Renata Cifkova,Nuno Lunet,Mongal Singh Gurung,Joseph Kibachio Mwangi,J. Martins,Rosa Haghshenas,Lela Sturua,Sebastian Vollmer,Till Bärnighausen,Rifat Atun,Jeremy B. Sussman,Kavita Singh,Sahar Saeedi Moghaddam,David Guwatudde,Pascal Geldsetzer,Jennifer Manne-Goehler,Mark D. Huffman,J. Davies,David Flood +33 more
- 22 Aug 2023
TL;DR: Worldwide, aspirin is underused in secondary prevention, particularly in low-income countries, and national health policies and health systems must develop, implement, and evaluate strategies to promote aspirin therapy.
13
Mood disorders impaired quality of life but not the mortality or morbidity risk in stable coronary heart disease patients.
Otto Mayer,Jan Bruthans,Jan Bruthans,Jitka Seidlerová,Petra Karnosová,Markéta Mateřánková,Julius Gelžinský,Martina Rychecká,Renata Cifkova,Jan Filipovský +9 more
TL;DR: Mood disorders severely affected QoL of stable CHD patients, but not their global cardiovascular risk, and any cardiovascular risk disappeared if adjusted for potential covariates.
13
Hypertension in the metabolic syndrome: summary of the new position statement of the European Society of Hypertension.
TL;DR: Prevalence of arterial hypertension is higher than in the general population and the metabolic syndrome can be found in as many as one third of patients, and a high prevalence of hypertension-induced target organ damage and a negative prognostic value have been described.
13
Why is the treatment of hypertension in pregnancy still so difficult
TL;DR: Sufficient data regarding treatment of hypertension in pregnancy are lacking as pharmaceutical companies have been reluctant to test drugs in this small market with a high potential of litigation and Pharmaceutical companies are not willing to take any risk and, therefore, no data are available for most of the antihypertensive drugs marketed over the last 20 years.
12